Frameshift events predict anti-PD-1/L1 response in head and neck cancer

JCI Insight
Glenn J HannaRobert I Haddad

Abstract

Programmed cell death protein 1 (PD-1) inhibitors have efficacy in treating squamous cell carcinoma of the head and neck (SCCHN), but objective response rates are low. PD-1 ligand (PD-L1) expression alone is not considered a robust predictor of response and additional biomarkers are needed. This 3-year observational cohort followed 126 SCCHN patients treated with anti-PD-1/L1 therapy. Prior to treatment, 81 (64%) had targeted massively parallel tumor sequencing. Of these, 42 (52%) underwent fluorescence-activated cell sorting and PD-L1 immunohistochemistry for tumor immunoprofiling. Six (5%) complete responses (CRs) and 11 (9%) partial responses (PRs) were observed. Those treated with prior chemotherapy (98, 78%) versus only surgery and/or radiation had longer overall survival (OS) (10 vs. 3 months, P = 0.02). Smokers had a higher total mutational burden (TMB) (P = 0.01). Virus-positive patients had a lower TMB (P < 0.01) and improved OS (P = 0.02). Among virus-negative responders, NOTCH1 and SMARCA4 were more frequently mutated and frameshift events in tumor suppressor genes occurred more frequently (P = 0.03). Higher TMB and CD8+ T cell infiltrates predicted anti-PD-1/L1 benefit (P < 0.01, P < 0.01, respectively) among virus-...Continue Reading

References

Jul 30, 2011·Science·Nicolas StranskyJennifer R Grandis
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Sep 21, 2013·Nature Immunology·Thomas F GajewskiYang-Xin Fu
Jun 21, 2015·Cancer Discovery·Charles SwantonReuben S Harris
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L Ferris
Jan 21, 2016·Cancer Immunology Research·Antoni RibasBegoña Comin-Anduix
Feb 6, 2016·Nature Medicine·Kimberly H Kim, Charles W M Roberts
Feb 14, 2016·Immunity·Christina PfirschkeMikael J Pittet
Jun 24, 2016·British Journal of Cancer·Shivshankari Rajkumar, Ian R Watson
Jun 29, 2016·Nature·Els M E VerdegaalSjoerd H van der Burg
Jul 6, 2016·British Journal of Cancer·Vishwajith SridharanJonathan D Schoenfeld
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Aug 16, 2016·The Journal of Clinical Investigation·Adil I DaudMichael D Rosenblum
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M ChowTanguy Y Seiwert
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Feb 12, 2017·Cancer Immunology, Immunotherapy : CII·Genevieve HartleySteven Dow
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
Apr 20, 2017·Genome Medicine·Zachary R ChalmersGarrett M Frampton
May 31, 2017·Archives of Pathology & Laboratory Medicine·Elizabeth P GarciaFei Dong

❮ Previous
Next ❯

Citations

Jul 31, 2019·Expert Opinion on Biological Therapy·James Ch ChowWilliam Cs Cho
Sep 22, 2019·International Journal of Molecular Sciences·Bilikis Aderonke AbolarinwaYen-Hua Huang
Jan 31, 2020·International Journal of Cancer. Journal International Du Cancer·Eleonore De GuillebonEric Tartour
Jun 2, 2020·International Journal of Cancer. Journal International Du Cancer·Nicole D FacompreDevraj Basu
Sep 15, 2020·Science China. Life Sciences·Zhangsong WuSong Wu
Sep 7, 2018·JCI Insight·Glenn J HannaLaura E MacConaill
Jun 12, 2019·Journal of Hematology & Oncology·Peipei GaoPeng Wu
Apr 27, 2019·Frontiers in Cell and Developmental Biology·Madison CanningYan Cui
Feb 14, 2019·Nature Reviews. Cancer·Jonathan J HavelTimothy A Chan
May 27, 2020·American Society of Clinical Oncology Educational Book·William B McKeanSiwen Hu-Lieskovan
Jul 3, 2020·Biomarker Research·Jing ZhangShiaw-Yih Lin
Nov 2, 2019·International Journal of Molecular Sciences·Valerie CristinaMarco Siano
Oct 13, 2020·Frontiers in Oncology·Jeremy Gbenakpon AugustinCécile Badoual
Oct 20, 2020·Frontiers in Immunology·Xin-Wei QiaoYa-Ling Tang
Oct 9, 2020·Human Molecular Genetics·Renzo G DiNataleTimothy A Chan
Feb 6, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Romualdo Barroso-SousaSara M Tolaney
Dec 29, 2020·Frontiers in Cell and Developmental Biology·Yueming ZhangJian Zhang
May 10, 2020·Seminars in Radiation Oncology·Raghvendra M SrivastavaTimothy A Chan
Aug 1, 2019·The Lancet Oncology·Sana D Karam, David Raben
Nov 4, 2020·Cancer Discovery·Dan ShaFrank A Sinicrope
Nov 19, 2019·Critical Reviews in Oncology/hematology·Martina NapolitanoFederica Bertolini
Dec 2, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tanya E KeenanSara M Tolaney
Dec 17, 2020·Cells·Pooja A ShahMitchell J Frederick

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
biopsy
Exome Sequencing
PCR

Software Mentioned

BWA
OncoPanel
FACSDiva
FlowJo
Hancock
Picard
SomaticIndelDetector
BreaKmer viewer IGV
COSMIC
RobustCNV

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

© 2022 Meta ULC. All rights reserved